The combination of anti-PDL1 plus anti-angiogenic therapies with high-dose tumor irradiation could strengthen its antitumor immune effect by subverting the compensatory radio-induced immunosuppressive tumor microenvironment [95]. This evidence concerns the gene CD274 and neoplasm.